2020-2027 Analysis and Review Propranolol Hydrochloride Market

Propranolol Hydrochloride Market

Propranolol Hydrochloride Market By Clinical Application (Hypertension, Migraine and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

11-07-2020 REP-HC-5131 40 Tables 115 pages Format

The propranolol hydrochloride market was valued at USD 707.4 Mn by 2019. The rising prevalence of cardiac complications worldwide primarily determines the propranolol hydrochloride market growth. Furthermore, the growing incidence of migraine attacks among young adults further propels the market growth.

Propranolol Hydrochloride Market

Propranolol hydrochloride is a racemic mixture of having 100 times more binding affinity for the beta-adrenergic receptors. The drug has a protein binding capacity of 90% hence, it needs to be taken under medical supervision as abrupt noncompliance of propranolol hydrochloride may result in the worsening of angina and myocardial infarctions. It is available as tablets, extended-release capsules, and oral solutions.

The major segments related to the propranolol hydrochloride market are: 

By Clinical Application (2017–2027; US$ Mn)

Hypertension

Migraine

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global propranolol hydrochloride market
  • The overall segmentation of the propranolol hydrochloride market, by clinical application, distribution channel, and geography is minutely studied. Hypertension and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Rising prevalence of hypertension worldwide
  • Growing incidence of migraine attacks across the globe further accentuates the propranolol hydrochloride market growth

Report gist?

  • The study of the global propranolol hydrochloride market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the generic drug manufacturers actively engaged in the production and marketing of propranolol hydrochloride due to the  rising prevalence of hypertension worldwide
  • The report will benefit physicians engaged in the prescription of propranolol hydrochloride in the treatment of migraine attacks across the globe
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to propranolol hydrochloride market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Hypertension is representing the largest market share in the clinical application segment for the propranolol hydrochloride market. As per the latest information presented by the World Health Organization (WHO), approximately 1.13 billion people worldwide are suffering from hypertension. A significant increase in stressful lifestyles, consumption of alcohol, and tobacco on a regular basis has led to the early onset of hypertension in the young adult population across the globe. Propranolol hydrochloride also finds clinical relevance in the treatment of angina pectoris, atrial fibrillation, proliferating infantile hemangioma, etc. A migraine will be recording exemplary market performance during the forecast period on account of increasing consumption of caffeinated drinks, exposure to sensory stimuli, and change in sleeping patterns, etc. According to the latest information provided by the Migraine Research Foundation (MRF), migraine is the 3rd most prevalent diseases occurring across the globe, further clinical studies have revealed that approximately 1 billion people throughout the globe are reported to be suffering from migraine.

Hospital pharmacy is currently dominating the distribution channel segment for the propranolol hydrochloride market. The drug is associated with drug overdose toxicity such as hypotension, insomnia, restlessness, etc. hence it is imperative for compulsory dispensing of propranolol hydrochloride under the supervision of a hospital pharmacist. Retail pharmacy is expected to register rampant market growth in the near future owing to its ability to provide generic medicines at low cost and capacity to serve medicinal requirements of households residing in remote locations.

North America is presently the clear leader in the geography segment for the propranolol hydrochloride market. Rising prevalence of cardiac complications primarily drives the propranolol hydrochloride market growth. As per the latest statistics provided by the American Heart Association (AHA), approximately 48% of American adult citizens suffer from some type of cardiovascular disease. Additionally, the domicile of key players such as Mylan Pharmaceutical Industries Limited, Lupin Pharma, Teva Pharmaceutical Industries Limited, etc further accentuates the market growth in the region. Europe is considered as the second-largest regional segment for the propranolol hydrochloride market on account of the growing incidence of migraine attacks occurring among the adult population in the region. The supportive regulatory environment provided by the European Medical Agency (EMA), for the sale and distribution of propranolol hydrochloride market growth. The Asia Pacific is anticipated to be the fastest-growing regional segment for the propranolol hydrochloride market. Developing healthcare infrastructure and flourishing generic drugs market together with determining the propranolol hydrochloride market growth in the Asia Pacific region.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.